Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Palliative Care | 97 | 2024 | 3493 | 9.180 |
Why?
|
Terminal Care | 40 | 2023 | 1694 | 5.120 |
Why?
|
Lung Neoplasms | 79 | 2022 | 13104 | 4.460 |
Why?
|
Gastrointestinal Neoplasms | 17 | 2023 | 990 | 4.270 |
Why?
|
Quality of Life | 96 | 2024 | 12802 | 4.000 |
Why?
|
Neoplasms | 89 | 2023 | 21696 | 3.790 |
Why?
|
Hospice Care | 17 | 2023 | 672 | 3.570 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 48 | 2022 | 5223 | 3.180 |
Why?
|
Caregivers | 26 | 2023 | 2095 | 2.930 |
Why?
|
Adaptation, Psychological | 22 | 2022 | 2575 | 2.090 |
Why?
|
Hematopoietic Stem Cell Transplantation | 17 | 2024 | 5445 | 1.770 |
Why?
|
Hospices | 6 | 2020 | 265 | 1.770 |
Why?
|
Affect | 13 | 2019 | 1475 | 1.670 |
Why?
|
Advance Care Planning | 16 | 2022 | 662 | 1.580 |
Why?
|
Anxiety | 27 | 2023 | 4293 | 1.530 |
Why?
|
Depression | 37 | 2023 | 7759 | 1.510 |
Why?
|
Leukemia, Myeloid, Acute | 8 | 2023 | 3524 | 1.500 |
Why?
|
Hematologic Neoplasms | 9 | 2024 | 1832 | 1.380 |
Why?
|
Hospitalization | 23 | 2024 | 10259 | 1.330 |
Why?
|
Delivery of Health Care, Integrated | 7 | 2020 | 941 | 1.240 |
Why?
|
Medical Oncology | 17 | 2023 | 2267 | 1.140 |
Why?
|
Family | 8 | 2020 | 3147 | 1.120 |
Why?
|
Dyspnea | 4 | 2022 | 1303 | 1.090 |
Why?
|
Aged | 122 | 2022 | 163288 | 0.970 |
Why?
|
Humans | 254 | 2024 | 744366 | 0.920 |
Why?
|
Antineoplastic Agents | 21 | 2020 | 13693 | 0.900 |
Why?
|
Middle Aged | 129 | 2024 | 213390 | 0.900 |
Why?
|
Medication Adherence | 12 | 2024 | 2063 | 0.880 |
Why?
|
Inpatients | 7 | 2024 | 2518 | 0.860 |
Why?
|
Patient Preference | 6 | 2020 | 889 | 0.840 |
Why?
|
Outpatients | 5 | 2022 | 1487 | 0.810 |
Why?
|
Male | 143 | 2023 | 350115 | 0.790 |
Why?
|
Resuscitation Orders | 5 | 2019 | 269 | 0.790 |
Why?
|
Ambulatory Care | 8 | 2022 | 2708 | 0.780 |
Why?
|
Patient Acceptance of Health Care | 6 | 2019 | 3020 | 0.780 |
Why?
|
Female | 147 | 2024 | 380193 | 0.750 |
Why?
|
Neoplasm Metastasis | 9 | 2017 | 4851 | 0.740 |
Why?
|
Stress, Psychological | 12 | 2022 | 4245 | 0.730 |
Why?
|
Prognosis | 33 | 2023 | 29060 | 0.710 |
Why?
|
Cachexia | 3 | 2017 | 205 | 0.670 |
Why?
|
Fatigue | 10 | 2024 | 1531 | 0.660 |
Why?
|
Stress Disorders, Post-Traumatic | 5 | 2021 | 4266 | 0.660 |
Why?
|
Edema | 1 | 2022 | 789 | 0.640 |
Why?
|
Aged, 80 and over | 54 | 2021 | 57776 | 0.630 |
Why?
|
Documentation | 4 | 2022 | 871 | 0.620 |
Why?
|
Hydrazines | 2 | 2017 | 226 | 0.610 |
Why?
|
Cardiopulmonary Resuscitation | 8 | 2018 | 980 | 0.610 |
Why?
|
Videotape Recording | 4 | 2016 | 352 | 0.610 |
Why?
|
Self Report | 7 | 2022 | 3553 | 0.590 |
Why?
|
Pilot Projects | 17 | 2023 | 8319 | 0.580 |
Why?
|
Models, Organizational | 2 | 2020 | 574 | 0.570 |
Why?
|
Reminder Systems | 1 | 2020 | 371 | 0.570 |
Why?
|
Randomized Controlled Trials as Topic | 20 | 2024 | 9955 | 0.560 |
Why?
|
Breast Neoplasms | 12 | 2024 | 20824 | 0.540 |
Why?
|
Goals | 2 | 2020 | 707 | 0.530 |
Why?
|
Monitoring, Ambulatory | 1 | 2019 | 355 | 0.530 |
Why?
|
Patients | 5 | 2023 | 900 | 0.520 |
Why?
|
Terminally Ill | 2 | 2014 | 238 | 0.490 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2018 | 360 | 0.490 |
Why?
|
Patient-Centered Care | 3 | 2022 | 1438 | 0.490 |
Why?
|
Oligopeptides | 2 | 2017 | 1189 | 0.470 |
Why?
|
Patient Satisfaction | 7 | 2022 | 3395 | 0.460 |
Why?
|
Needs Assessment | 2 | 2017 | 1147 | 0.460 |
Why?
|
Home Care Services, Hospital-Based | 1 | 2013 | 44 | 0.450 |
Why?
|
Hand Strength | 1 | 2016 | 448 | 0.440 |
Why?
|
Decision Making | 11 | 2021 | 3888 | 0.440 |
Why?
|
Telemedicine | 5 | 2022 | 2872 | 0.430 |
Why?
|
Geriatric Assessment | 1 | 2020 | 1372 | 0.420 |
Why?
|
Professional Role | 2 | 2014 | 306 | 0.420 |
Why?
|
Cough | 2 | 2013 | 555 | 0.400 |
Why?
|
Patient Readmission | 4 | 2022 | 3116 | 0.400 |
Why?
|
Patient Participation | 2 | 2018 | 1457 | 0.400 |
Why?
|
Karnofsky Performance Status | 3 | 2020 | 173 | 0.400 |
Why?
|
Clinical Coding | 1 | 2013 | 171 | 0.400 |
Why?
|
Glioma | 3 | 2022 | 3401 | 0.400 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 14 | 2022 | 11525 | 0.390 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2021 | 1581 | 0.390 |
Why?
|
Evidence-Based Medicine | 3 | 2020 | 3611 | 0.380 |
Why?
|
Geriatrics | 1 | 2015 | 397 | 0.380 |
Why?
|
Health Knowledge, Attitudes, Practice | 8 | 2019 | 3922 | 0.370 |
Why?
|
Withholding Treatment | 1 | 2015 | 599 | 0.370 |
Why?
|
Hemoptysis | 1 | 2011 | 155 | 0.370 |
Why?
|
Adult | 59 | 2023 | 214052 | 0.360 |
Why?
|
Qualitative Research | 7 | 2020 | 2682 | 0.360 |
Why?
|
Treatment Outcome | 26 | 2022 | 63107 | 0.360 |
Why?
|
Survival Analysis | 12 | 2021 | 10252 | 0.360 |
Why?
|
Teaching | 1 | 2017 | 1174 | 0.360 |
Why?
|
Feasibility Studies | 11 | 2021 | 5077 | 0.350 |
Why?
|
Quality Assurance, Health Care | 2 | 2020 | 2212 | 0.350 |
Why?
|
Anxiety Disorders | 4 | 2016 | 2690 | 0.350 |
Why?
|
Research | 2 | 2017 | 1999 | 0.350 |
Why?
|
Behavior Therapy | 1 | 2015 | 865 | 0.340 |
Why?
|
Attitude to Health | 2 | 2020 | 2052 | 0.340 |
Why?
|
Severity of Illness Index | 8 | 2019 | 15535 | 0.340 |
Why?
|
Hospital Mortality | 3 | 2019 | 5316 | 0.340 |
Why?
|
Pyrazoles | 2 | 2021 | 1972 | 0.330 |
Why?
|
Patient Admission | 1 | 2016 | 1380 | 0.320 |
Why?
|
Lung | 4 | 2023 | 9857 | 0.310 |
Why?
|
Physician-Patient Relations | 5 | 2022 | 3229 | 0.310 |
Why?
|
Transplantation Conditioning | 1 | 2014 | 1599 | 0.310 |
Why?
|
Communication | 10 | 2022 | 3750 | 0.300 |
Why?
|
Time Factors | 14 | 2019 | 40075 | 0.290 |
Why?
|
Early Detection of Cancer | 3 | 2020 | 3086 | 0.290 |
Why?
|
Cost of Illness | 5 | 2022 | 1860 | 0.280 |
Why?
|
Weight Loss | 3 | 2021 | 2625 | 0.280 |
Why?
|
Perception | 3 | 2020 | 1198 | 0.280 |
Why?
|
Neoplasm Staging | 13 | 2019 | 11031 | 0.270 |
Why?
|
Electronic Health Records | 7 | 2022 | 4468 | 0.270 |
Why?
|
Prospective Studies | 18 | 2022 | 53290 | 0.270 |
Why?
|
Psychometrics | 4 | 2021 | 3003 | 0.270 |
Why?
|
Administration, Oral | 6 | 2020 | 3914 | 0.270 |
Why?
|
End Stage Liver Disease | 2 | 2019 | 314 | 0.250 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2021 | 5172 | 0.250 |
Why?
|
Renal Insufficiency, Chronic | 4 | 2021 | 2200 | 0.250 |
Why?
|
Patient Care Planning | 3 | 2017 | 921 | 0.250 |
Why?
|
Length of Stay | 5 | 2022 | 6311 | 0.250 |
Why?
|
Health Status | 2 | 2017 | 4034 | 0.250 |
Why?
|
Referral and Consultation | 7 | 2019 | 3531 | 0.240 |
Why?
|
Patient Education as Topic | 4 | 2019 | 2278 | 0.240 |
Why?
|
Sarcopenia | 2 | 2021 | 368 | 0.240 |
Why?
|
Thoracic Neoplasms | 1 | 2006 | 268 | 0.230 |
Why?
|
Cross-Sectional Studies | 13 | 2021 | 25039 | 0.230 |
Why?
|
Pyridines | 1 | 2014 | 2825 | 0.210 |
Why?
|
Quinazolines | 5 | 2016 | 1356 | 0.210 |
Why?
|
Carcinoma, Small Cell | 1 | 2004 | 420 | 0.210 |
Why?
|
Psychiatric Status Rating Scales | 3 | 2017 | 6036 | 0.210 |
Why?
|
Exercise Therapy | 1 | 2009 | 904 | 0.210 |
Why?
|
Depressive Disorder | 2 | 2012 | 3747 | 0.210 |
Why?
|
Health Personnel | 3 | 2020 | 3219 | 0.200 |
Why?
|
Intensive Care Units | 4 | 2022 | 3680 | 0.200 |
Why?
|
Analgesics, Opioid | 2 | 2019 | 3677 | 0.200 |
Why?
|
Continuity of Patient Care | 2 | 2022 | 1049 | 0.190 |
Why?
|
Death | 3 | 2021 | 678 | 0.190 |
Why?
|
Critical Illness | 4 | 2022 | 2670 | 0.190 |
Why?
|
Combined Modality Therapy | 5 | 2022 | 8642 | 0.190 |
Why?
|
Chemotherapy, Adjuvant | 7 | 2024 | 3480 | 0.190 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11366 | 0.190 |
Why?
|
Temperance | 1 | 2020 | 89 | 0.190 |
Why?
|
Lactams | 1 | 2021 | 156 | 0.180 |
Why?
|
Disease Management | 4 | 2020 | 2460 | 0.180 |
Why?
|
Molecular Targeted Therapy | 3 | 2022 | 2725 | 0.180 |
Why?
|
Longitudinal Studies | 5 | 2019 | 13991 | 0.180 |
Why?
|
Smoking Cessation | 3 | 2020 | 2071 | 0.180 |
Why?
|
Patient Compliance | 2 | 2021 | 2684 | 0.180 |
Why?
|
Life Expectancy | 4 | 2013 | 1184 | 0.180 |
Why?
|
Salvage Therapy | 3 | 2011 | 1275 | 0.180 |
Why?
|
Social Support | 3 | 2020 | 2118 | 0.170 |
Why?
|
Depressive Disorder, Major | 4 | 2014 | 4639 | 0.170 |
Why?
|
Massachusetts | 5 | 2021 | 8662 | 0.170 |
Why?
|
Pancreatic Neoplasms | 3 | 2022 | 5263 | 0.170 |
Why?
|
Counseling | 2 | 2020 | 1523 | 0.160 |
Why?
|
Boston | 5 | 2021 | 9312 | 0.160 |
Why?
|
Genotype | 5 | 2017 | 12952 | 0.160 |
Why?
|
Electronics | 1 | 2020 | 322 | 0.160 |
Why?
|
Neck | 1 | 2022 | 698 | 0.160 |
Why?
|
Veterans Health | 1 | 2019 | 216 | 0.150 |
Why?
|
Receptors, Ghrelin | 1 | 2017 | 25 | 0.150 |
Why?
|
United States | 17 | 2021 | 69872 | 0.150 |
Why?
|
Trauma, Nervous System | 1 | 2017 | 36 | 0.150 |
Why?
|
Head and Neck Neoplasms | 2 | 2022 | 2736 | 0.150 |
Why?
|
Nursing Methodology Research | 1 | 2017 | 67 | 0.150 |
Why?
|
Personal Satisfaction | 1 | 2022 | 643 | 0.150 |
Why?
|
Protein Kinase Inhibitors | 6 | 2021 | 5534 | 0.150 |
Why?
|
Aminopyridines | 1 | 2021 | 542 | 0.150 |
Why?
|
Calciphylaxis | 1 | 2018 | 124 | 0.140 |
Why?
|
Drug Therapy | 1 | 2020 | 497 | 0.140 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2021 | 2455 | 0.140 |
Why?
|
Retrospective Studies | 18 | 2021 | 77460 | 0.140 |
Why?
|
Muscle, Skeletal | 3 | 2021 | 4925 | 0.140 |
Why?
|
Young Adult | 10 | 2021 | 56429 | 0.140 |
Why?
|
Self Efficacy | 1 | 2020 | 615 | 0.140 |
Why?
|
Leukemia, Myeloid | 1 | 2019 | 707 | 0.140 |
Why?
|
Small Cell Lung Carcinoma | 2 | 2011 | 388 | 0.140 |
Why?
|
Actigraphy | 1 | 2019 | 488 | 0.130 |
Why?
|
Patient Advocacy | 1 | 2018 | 353 | 0.130 |
Why?
|
Professional-Patient Relations | 3 | 2018 | 737 | 0.130 |
Why?
|
Follow-Up Studies | 11 | 2019 | 39052 | 0.130 |
Why?
|
Anorexia | 1 | 2016 | 161 | 0.130 |
Why?
|
Physical Fitness | 1 | 2019 | 732 | 0.130 |
Why?
|
Activities of Daily Living | 3 | 2019 | 2419 | 0.130 |
Why?
|
Interdisciplinary Communication | 2 | 2018 | 950 | 0.130 |
Why?
|
Odds Ratio | 6 | 2019 | 9849 | 0.120 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2016 | 358 | 0.120 |
Why?
|
Intestinal Obstruction | 1 | 2018 | 423 | 0.120 |
Why?
|
Family Health | 2 | 2016 | 1281 | 0.120 |
Why?
|
Digestive System Surgical Procedures | 1 | 2019 | 576 | 0.120 |
Why?
|
Attitude | 1 | 2019 | 776 | 0.120 |
Why?
|
Focus Groups | 2 | 2017 | 1321 | 0.110 |
Why?
|
Primary Myelofibrosis | 1 | 2015 | 215 | 0.110 |
Why?
|
Linear Models | 2 | 2016 | 5953 | 0.110 |
Why?
|
Survivors | 3 | 2021 | 2291 | 0.110 |
Why?
|
Interpersonal Relations | 2 | 2018 | 1425 | 0.110 |
Why?
|
Survival Rate | 8 | 2013 | 12788 | 0.110 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1782 | 0.110 |
Why?
|
Smoking | 4 | 2020 | 8987 | 0.110 |
Why?
|
Secondary Prevention | 3 | 2019 | 1530 | 0.110 |
Why?
|
Health Literacy | 1 | 2018 | 414 | 0.110 |
Why?
|
Androgen Antagonists | 1 | 2021 | 1377 | 0.110 |
Why?
|
Nursing Homes | 1 | 2019 | 1036 | 0.110 |
Why?
|
Reproducibility of Results | 5 | 2022 | 19905 | 0.100 |
Why?
|
Monitoring, Physiologic | 1 | 2020 | 1739 | 0.100 |
Why?
|
Educational Status | 2 | 2017 | 2540 | 0.100 |
Why?
|
Health Care Costs | 3 | 2014 | 3208 | 0.100 |
Why?
|
Perioperative Care | 1 | 2019 | 1002 | 0.100 |
Why?
|
Comprehension | 2 | 2018 | 610 | 0.100 |
Why?
|
Clinical Trials as Topic | 6 | 2021 | 7914 | 0.100 |
Why?
|
Electronic Mail | 1 | 2013 | 213 | 0.100 |
Why?
|
Mental Disorders | 2 | 2022 | 6598 | 0.100 |
Why?
|
Carboplatin | 2 | 2015 | 801 | 0.100 |
Why?
|
Socioeconomic Factors | 5 | 2019 | 7785 | 0.090 |
Why?
|
Transplantation, Autologous | 1 | 2015 | 2124 | 0.090 |
Why?
|
Mutation | 11 | 2021 | 29786 | 0.090 |
Why?
|
Panic Disorder | 1 | 2014 | 616 | 0.090 |
Why?
|
Body Composition | 1 | 2020 | 2402 | 0.090 |
Why?
|
Adenocarcinoma | 4 | 2012 | 6364 | 0.090 |
Why?
|
Naphthyridines | 1 | 2011 | 118 | 0.090 |
Why?
|
Brain Neoplasms | 4 | 2023 | 8861 | 0.090 |
Why?
|
Biopsy | 3 | 2021 | 6755 | 0.090 |
Why?
|
Disease Progression | 4 | 2022 | 13286 | 0.090 |
Why?
|
Decision Support Techniques | 2 | 2020 | 1956 | 0.090 |
Why?
|
Intubation, Intratracheal | 2 | 2016 | 1364 | 0.090 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2024 | 1524 | 0.090 |
Why?
|
Diagnosis, Differential | 3 | 2022 | 12961 | 0.090 |
Why?
|
Age Factors | 4 | 2015 | 18373 | 0.090 |
Why?
|
Critical Care | 2 | 2022 | 2647 | 0.090 |
Why?
|
Delayed-Action Preparations | 1 | 2013 | 968 | 0.090 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 3616 | 0.090 |
Why?
|
Comorbidity | 5 | 2019 | 10388 | 0.090 |
Why?
|
Quinoxalines | 1 | 2011 | 290 | 0.080 |
Why?
|
Professional-Family Relations | 1 | 2013 | 482 | 0.080 |
Why?
|
Attitude of Health Personnel | 2 | 2020 | 3841 | 0.080 |
Why?
|
Logistic Models | 4 | 2020 | 13409 | 0.080 |
Why?
|
Nicotinic Agonists | 1 | 2011 | 271 | 0.080 |
Why?
|
Program Evaluation | 1 | 2017 | 2488 | 0.080 |
Why?
|
Research Design | 2 | 2017 | 5984 | 0.080 |
Why?
|
Benzazepines | 1 | 2011 | 326 | 0.080 |
Why?
|
Home Care Services | 1 | 2015 | 606 | 0.080 |
Why?
|
Hydroxychloroquine | 1 | 2012 | 412 | 0.080 |
Why?
|
Colorectal Neoplasms | 2 | 2021 | 6773 | 0.080 |
Why?
|
Community Health Services | 1 | 2014 | 650 | 0.080 |
Why?
|
Fee-for-Service Plans | 1 | 2014 | 694 | 0.080 |
Why?
|
Pain | 3 | 2022 | 4988 | 0.080 |
Why?
|
Patient Discharge | 2 | 2020 | 3318 | 0.080 |
Why?
|
Proto-Oncogene Proteins | 1 | 2021 | 4554 | 0.080 |
Why?
|
Cost Savings | 1 | 2013 | 925 | 0.080 |
Why?
|
Blood Cell Count | 1 | 2009 | 403 | 0.080 |
Why?
|
Sexual Behavior | 1 | 2018 | 2055 | 0.080 |
Why?
|
Patient Care Team | 4 | 2017 | 2531 | 0.080 |
Why?
|
Sex Characteristics | 2 | 2015 | 2585 | 0.080 |
Why?
|
Liver Transplantation | 1 | 2019 | 2119 | 0.080 |
Why?
|
Multicenter Studies as Topic | 2 | 2024 | 1677 | 0.080 |
Why?
|
Immunotherapy | 3 | 2021 | 4446 | 0.080 |
Why?
|
Adipose Tissue | 1 | 2020 | 3280 | 0.080 |
Why?
|
Clinical Protocols | 1 | 2014 | 1461 | 0.080 |
Why?
|
Delivery of Health Care | 2 | 2018 | 5321 | 0.080 |
Why?
|
Interviews as Topic | 1 | 2014 | 2539 | 0.080 |
Why?
|
Evidence-Based Practice | 1 | 2012 | 501 | 0.070 |
Why?
|
Leukemia | 1 | 2015 | 1510 | 0.070 |
Why?
|
Mental Health | 2 | 2023 | 3010 | 0.070 |
Why?
|
Transplantation, Homologous | 1 | 2015 | 4777 | 0.070 |
Why?
|
Health Care Reform | 2 | 2014 | 1261 | 0.070 |
Why?
|
Risk Factors | 7 | 2020 | 72296 | 0.070 |
Why?
|
Glutathione | 1 | 2009 | 590 | 0.070 |
Why?
|
Decision Support Systems, Clinical | 2 | 2015 | 1164 | 0.070 |
Why?
|
Cause of Death | 1 | 2017 | 3582 | 0.070 |
Why?
|
Ambulatory Care Facilities | 1 | 2013 | 934 | 0.070 |
Why?
|
Attitude to Death | 1 | 2009 | 382 | 0.070 |
Why?
|
Graft vs Host Disease | 1 | 2019 | 2958 | 0.070 |
Why?
|
Lymphoma | 1 | 2015 | 1877 | 0.070 |
Why?
|
Paclitaxel | 2 | 2015 | 1708 | 0.070 |
Why?
|
Physicians | 2 | 2019 | 4567 | 0.070 |
Why?
|
Cohort Studies | 5 | 2017 | 40559 | 0.070 |
Why?
|
Probability | 2 | 2009 | 2506 | 0.070 |
Why?
|
Antidepressive Agents | 1 | 2018 | 2838 | 0.070 |
Why?
|
Emergency Service, Hospital | 2 | 2020 | 7658 | 0.070 |
Why?
|
Risk Assessment | 4 | 2017 | 23336 | 0.070 |
Why?
|
Myelodysplastic Syndromes | 1 | 2015 | 1352 | 0.070 |
Why?
|
Medical Informatics | 1 | 2012 | 745 | 0.070 |
Why?
|
Self Care | 2 | 2022 | 786 | 0.070 |
Why?
|
Substance-Related Disorders | 1 | 2022 | 4257 | 0.070 |
Why?
|
Double-Blind Method | 2 | 2017 | 12025 | 0.060 |
Why?
|
Practice Guidelines as Topic | 3 | 2013 | 7282 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 14723 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 3 | 2011 | 6539 | 0.060 |
Why?
|
Sirolimus | 1 | 2012 | 1565 | 0.060 |
Why?
|
Antibodies, Monoclonal | 3 | 2011 | 9274 | 0.060 |
Why?
|
Angiogenesis Inhibitors | 1 | 2015 | 2038 | 0.060 |
Why?
|
Reference Values | 1 | 2012 | 4982 | 0.060 |
Why?
|
Healthcare Disparities | 2 | 2018 | 3154 | 0.060 |
Why?
|
Curriculum | 1 | 2017 | 3605 | 0.060 |
Why?
|
California | 2 | 2019 | 1402 | 0.060 |
Why?
|
Neovascularization, Pathologic | 1 | 2015 | 2638 | 0.060 |
Why?
|
Uncertainty | 2 | 2021 | 735 | 0.060 |
Why?
|
Emotions | 1 | 2016 | 2659 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2019 | 3143 | 0.060 |
Why?
|
Databases, Factual | 2 | 2019 | 7730 | 0.060 |
Why?
|
Rectal Neoplasms | 1 | 2013 | 1205 | 0.060 |
Why?
|
Health Policy | 2 | 2013 | 2661 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2015 | 3511 | 0.060 |
Why?
|
Pharmacogenetics | 1 | 2008 | 674 | 0.060 |
Why?
|
Thiazoles | 1 | 2011 | 1483 | 0.060 |
Why?
|
Neutropenia | 1 | 2008 | 895 | 0.060 |
Why?
|
Melanoma | 1 | 2021 | 5511 | 0.050 |
Why?
|
Health Care Surveys | 3 | 2019 | 2453 | 0.050 |
Why?
|
Carcinoma, Papillary | 1 | 2008 | 783 | 0.050 |
Why?
|
Kidney Neoplasms | 1 | 2019 | 4262 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2010 | 9240 | 0.050 |
Why?
|
Drug Eruptions | 1 | 2005 | 297 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2019 | 629 | 0.050 |
Why?
|
Quality of Health Care | 1 | 2017 | 4369 | 0.050 |
Why?
|
Interdisciplinary Studies | 1 | 2021 | 89 | 0.050 |
Why?
|
Stomach Neoplasms | 1 | 2011 | 1332 | 0.050 |
Why?
|
Renal Dialysis | 2 | 2021 | 1783 | 0.050 |
Why?
|
Ovarian Neoplasms | 1 | 2018 | 4839 | 0.050 |
Why?
|
Bone Marrow Purging | 1 | 2000 | 109 | 0.050 |
Why?
|
Esophageal Neoplasms | 1 | 2011 | 1585 | 0.050 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2019 | 841 | 0.050 |
Why?
|
Leucovorin | 1 | 2022 | 628 | 0.050 |
Why?
|
Sex Factors | 2 | 2012 | 10400 | 0.050 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2021 | 318 | 0.050 |
Why?
|
Drug Administration Schedule | 1 | 2008 | 4933 | 0.050 |
Why?
|
Respiratory Tract Diseases | 1 | 2006 | 722 | 0.050 |
Why?
|
Social Work | 1 | 2021 | 162 | 0.040 |
Why?
|
Cotinine | 1 | 2020 | 206 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2020 | 20130 | 0.040 |
Why?
|
New Mexico | 1 | 2019 | 86 | 0.040 |
Why?
|
Enzyme Inhibitors | 2 | 2012 | 3799 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2009 | 10943 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2022 | 15297 | 0.040 |
Why?
|
Inflammation | 2 | 2017 | 10637 | 0.040 |
Why?
|
Baltimore | 1 | 2019 | 231 | 0.040 |
Why?
|
Tape Recording | 1 | 2018 | 76 | 0.040 |
Why?
|
Therapeutics | 1 | 2019 | 116 | 0.040 |
Why?
|
Pneumonia, Aspiration | 1 | 2019 | 145 | 0.040 |
Why?
|
Antigens, CD34 | 1 | 2000 | 659 | 0.040 |
Why?
|
Models, Statistical | 1 | 2013 | 5101 | 0.040 |
Why?
|
Bupropion | 1 | 2020 | 303 | 0.040 |
Why?
|
Maximum Tolerated Dose | 2 | 2012 | 892 | 0.040 |
Why?
|
Dehydration | 1 | 2019 | 233 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 11126 | 0.040 |
Why?
|
Multiple Myeloma | 1 | 2015 | 5181 | 0.040 |
Why?
|
Pandemics | 3 | 2022 | 8385 | 0.040 |
Why?
|
Self-Assessment | 1 | 2019 | 390 | 0.040 |
Why?
|
New England | 1 | 2020 | 1022 | 0.040 |
Why?
|
Fluorouracil | 1 | 2022 | 1619 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2012 | 12356 | 0.040 |
Why?
|
Drug Tolerance | 1 | 2019 | 376 | 0.040 |
Why?
|
Telephone | 1 | 2020 | 617 | 0.040 |
Why?
|
Cytarabine | 1 | 2019 | 692 | 0.040 |
Why?
|
Guideline Adherence | 1 | 2007 | 2265 | 0.040 |
Why?
|
Adjuvants, Immunologic | 1 | 2022 | 1000 | 0.040 |
Why?
|
Incidence | 1 | 2015 | 20952 | 0.040 |
Why?
|
Anthracyclines | 1 | 2019 | 288 | 0.040 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2021 | 1475 | 0.030 |
Why?
|
Respiration, Artificial | 2 | 2018 | 2569 | 0.030 |
Why?
|
Saliva | 1 | 2020 | 809 | 0.030 |
Why?
|
Confidence Intervals | 2 | 2012 | 2971 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2021 | 1793 | 0.030 |
Why?
|
Cultural Competency | 1 | 2019 | 289 | 0.030 |
Why?
|
Psychological Tests | 1 | 2018 | 651 | 0.030 |
Why?
|
Gastrostomy | 1 | 2018 | 310 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2021 | 3130 | 0.030 |
Why?
|
Vasoconstrictor Agents | 1 | 2018 | 642 | 0.030 |
Why?
|
Organ Specificity | 1 | 2020 | 2008 | 0.030 |
Why?
|
New York | 1 | 2017 | 886 | 0.030 |
Why?
|
Patient Selection | 2 | 2020 | 4216 | 0.030 |
Why?
|
Waiting Lists | 1 | 2019 | 692 | 0.030 |
Why?
|
Thyroid Neoplasms | 1 | 2008 | 2282 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2019 | 1184 | 0.030 |
Why?
|
Renal Insufficiency | 1 | 2019 | 804 | 0.030 |
Why?
|
Physicians, Primary Care | 1 | 2020 | 592 | 0.030 |
Why?
|
Observer Variation | 1 | 2019 | 2593 | 0.030 |
Why?
|
Urinary Tract Infections | 1 | 2019 | 788 | 0.030 |
Why?
|
Health Facility Size | 1 | 2013 | 64 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 2 | 2011 | 17446 | 0.030 |
Why?
|
Placebos | 1 | 2017 | 1676 | 0.030 |
Why?
|
Enteral Nutrition | 1 | 2018 | 767 | 0.030 |
Why?
|
Neuroblastoma | 1 | 2000 | 1226 | 0.030 |
Why?
|
Health Expenditures | 2 | 2017 | 2349 | 0.030 |
Why?
|
Data Collection | 2 | 2012 | 3339 | 0.030 |
Why?
|
Heart Failure | 1 | 2016 | 10895 | 0.030 |
Why?
|
Stem Cell Transplantation | 1 | 2021 | 1620 | 0.030 |
Why?
|
Albumins | 1 | 2015 | 568 | 0.030 |
Why?
|
Practice Management, Medical | 1 | 2014 | 196 | 0.030 |
Why?
|
Proxy | 1 | 2012 | 145 | 0.030 |
Why?
|
Informed Consent | 1 | 2018 | 995 | 0.030 |
Why?
|
Cooperative Behavior | 1 | 2019 | 1504 | 0.020 |
Why?
|
Prevalence | 3 | 2014 | 15221 | 0.020 |
Why?
|
Hospitals, Teaching | 1 | 2016 | 1180 | 0.020 |
Why?
|
Oncology Service, Hospital | 1 | 2011 | 57 | 0.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2021 | 2043 | 0.020 |
Why?
|
Gossypol | 1 | 2010 | 23 | 0.020 |
Why?
|
Medicare | 2 | 2019 | 6566 | 0.020 |
Why?
|
Algorithms | 3 | 2022 | 13882 | 0.020 |
Why?
|
Systems Integration | 1 | 2012 | 440 | 0.020 |
Why?
|
Models, Molecular | 1 | 2021 | 5451 | 0.020 |
Why?
|
Topotecan | 1 | 2010 | 137 | 0.020 |
Why?
|
Alleles | 1 | 2021 | 6933 | 0.020 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2013 | 500 | 0.020 |
Why?
|
Truth Disclosure | 1 | 2013 | 436 | 0.020 |
Why?
|
Pain Measurement | 1 | 2019 | 3420 | 0.020 |
Why?
|
Cytotoxins | 1 | 2009 | 153 | 0.020 |
Why?
|
Checklist | 1 | 2016 | 833 | 0.020 |
Why?
|
Phobic Disorders | 1 | 2011 | 439 | 0.020 |
Why?
|
Awareness | 1 | 2013 | 640 | 0.020 |
Why?
|
Acute Disease | 1 | 2019 | 7147 | 0.020 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2008 | 91 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2012 | 2327 | 0.020 |
Why?
|
Interview, Psychological | 1 | 2011 | 812 | 0.020 |
Why?
|
Carcinoma, Large Cell | 1 | 2008 | 113 | 0.020 |
Why?
|
Regression Analysis | 1 | 2018 | 6459 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 2013 | 1342 | 0.020 |
Why?
|
Pneumonia | 1 | 2019 | 2133 | 0.020 |
Why?
|
Thyroglobulin | 1 | 2008 | 114 | 0.020 |
Why?
|
Carcinoma, Medullary | 1 | 2008 | 123 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2009 | 1420 | 0.020 |
Why?
|
Organoplatinum Compounds | 1 | 2008 | 408 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2011 | 602 | 0.020 |
Why?
|
Adenoma, Oxyphilic | 1 | 2008 | 143 | 0.020 |
Why?
|
Self Concept | 1 | 2012 | 1025 | 0.020 |
Why?
|
Efficiency, Organizational | 1 | 2011 | 695 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2011 | 1771 | 0.020 |
Why?
|
Drug Costs | 1 | 2014 | 1105 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6896 | 0.020 |
Why?
|
User-Computer Interface | 1 | 2012 | 1431 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 2011 | 783 | 0.020 |
Why?
|
Sepsis | 1 | 2019 | 2593 | 0.020 |
Why?
|
Kidney | 1 | 2021 | 7184 | 0.020 |
Why?
|
Drug Approval | 1 | 2011 | 742 | 0.020 |
Why?
|
Remission Induction | 1 | 2010 | 2385 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3508 | 0.020 |
Why?
|
Thoracic Surgery | 1 | 2011 | 719 | 0.020 |
Why?
|
Insurance, Health | 1 | 2017 | 2494 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2021 | 16690 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2008 | 826 | 0.020 |
Why?
|
Information Dissemination | 1 | 2012 | 1099 | 0.020 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2008 | 324 | 0.020 |
Why?
|
Primary Prevention | 1 | 2011 | 1167 | 0.010 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 2064 | 0.010 |
Why?
|
Genes, ras | 1 | 2007 | 690 | 0.010 |
Why?
|
Forecasting | 1 | 2012 | 2951 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5388 | 0.010 |
Why?
|
Registries | 1 | 2018 | 8091 | 0.010 |
Why?
|
Social Behavior | 1 | 2009 | 1127 | 0.010 |
Why?
|
Employment | 1 | 2009 | 1132 | 0.010 |
Why?
|
Risk | 1 | 2014 | 9688 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2012 | 2727 | 0.010 |
Why?
|
Case-Control Studies | 2 | 2009 | 21748 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2021 | 25628 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2012 | 4153 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2009 | 6489 | 0.010 |
Why?
|
Health Surveys | 1 | 2009 | 4036 | 0.010 |
Why?
|
Software | 1 | 2012 | 4441 | 0.010 |
Why?
|
Primary Health Care | 1 | 2012 | 4557 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2011 | 5135 | 0.010 |
Why?
|
Carcinoma | 1 | 2006 | 2375 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 15078 | 0.010 |
Why?
|
Phenotype | 1 | 2011 | 16367 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2000 | 6313 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2006 | 6234 | 0.010 |
Why?
|
Child | 2 | 2011 | 77709 | 0.010 |
Why?
|
Stem Cells | 1 | 2000 | 3567 | 0.000 |
Why?
|
Brain | 1 | 2006 | 26388 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2006 | 35425 | 0.000 |
Why?
|
Animals | 1 | 2005 | 168768 | 0.000 |
Why?
|